Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants
Laura Thümmler, Nadine Beckmann, Carolin Sehl, Matthias Soddemann, Peer Braß, Maren Bormann, Leonie Brochhagen, Carina Elsner, Nicolas Hoertel, Céline Cougoule, Sandra Ciesek, Marek Widera, Ulf Dittmer, Monika Lindemann, Peter A Horn, Oliver Witzke, Stephanie Kadow, Markus Kamler, Erich Gulbins, Katrin Anne Becker, Adalbert Krawczyk
Viruses, doi:10.3390/v16040545
The pandemic caused by SARS-CoV-2 is still a major health problem. Newly emerging variants and long-COVID-19 represent a challenge for the global health system. In particular, individuals in developing countries with insufficient health care need easily accessible, affordable and effective treatments of COVID-19. Previous studies have demonstrated the efficacy of functional inhibitors of acid sphingomyelinase against infections with various viruses, including early variants of SARS-CoV-2. This work investigated whether the acid sphingomyelinase inhibitors fluoxetine and sertraline, usually used as antidepressant molecules in clinical practice, can inhibit the replication of the former and recently emerged SARS-CoV-2 variants in vitro. Fluoxetine and sertraline potently inhibited the infection with pseudotyped virus-like particles and SARS-CoV-2 variants D614G, alpha, delta, omicron BA.1 and omicron BA.5. These results highlight fluoxetine and sertraline as priority candidates for large-scale phase 3 clinical trials at different stages of SARS-CoV-2 infections, either alone or in combination with other medications.
spike protein. This is an interesting finding, as fluoxetine and sertraline were described to interfere with SARS-CoV-2 entry, and at least sertraline directly targeted the SARS-CoV-2 spike protein [7] . In addition to targeting the spike protein, fluoxetine and sertraline were described as functional inhibitors of the acid sphingomyelinase (ASM), which plays an important role during SARS-CoV-2 entry into the host cell [38, 39] . ASM is a glycoprotein that catalyzes sphingomyelin degradation to phosphorylcholine and ceramide, which is known to facilitate viral entry into the host cell [40] [41] [42] . SARS-CoV-2 activates the ASM/ceramide system, resulting in the formation of ceramide-enriched membrane domains that cluster ACE2 and thereby facilitate viral entry and infection [39, 40, 43] . Thus, inhibiting ASM represents a SARS-CoV-2 spike mutation-independent mechanism to interfere with viral entry and infection. In the context of other viral infections, our data indicate that FIASMAs are effective not only against, for example, rhinoviruses [44] or ebolaviruses [45] , but also against SARS-CoV-2. In line with prior studies, our findings suggest that fluoxetine and sertraline use in early-stage SARS-CoV-2 infections with recent variants may reduce the risk of a severe course of COVID-19 or death [46] . However, we have demonstrated the antiviral efficacy of fluoxetine and sertraline against the respective SARS-CoV-2 variants in cell culture. Nonetheless, deriving..
References
Albouz, Boutry, Dubois, Bourdon, Hauw et al., Lipid and lysosomal enzymes in human fibroblasts cultured with perhexiline maleate, Naunyn-Schmiedebergs Arch. Pharmacol,
doi:10.1007/BF00500076Becker, Carpinteiro, Hoffmann, Pöhlmann, Kornhuber et al., Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells, STAR Protoc,
doi:10.1016/j.xpro.2021.100356Berger Rentsch, Zimmer, A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon, PLoS ONE,
doi:10.1371/journal.pone.0025858Bergwerk, Gonen, Lustig, Amit, Lipsitch et al., Covid-19 Breakthrough Infections in Vaccinated Health Care Workers, N. Engl. J. Med,
doi:10.1056/NEJMoa2109072Bormann, Brochhagen, Alt, Otte, Thümmler et al., Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5, Front. Immunol,
doi:10.3389/fimmu.2023.1150667Calusic, Marcec, Luksa, Jurkovic, Kovac et al., Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls, Br. J. Clin. Pharmacol,
doi:10.1111/bcp.15126Carpinteiro, Edwards, Hoffmann, Kochs, Gripp et al., Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells, Cell Rep. Med,
doi:10.1016/j.xcrm.2020.100142Carpinteiro, Gripp, Hoffmann, Pöhlmann, Hoertel et al., Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells, J. Biol. Chem,
doi:10.1016/j.jbc.2021.100701Chen, Wu, Chen, Zhan, Wu et al., Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein, J. Virol,
doi:10.1128/jvi.01245-22Dash, Barqawi, Obaideen, Al Chame, Samara et al., COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates, J. Epidemiol. Glob. Health,
doi:10.1007/s44197-023-00090-8Fred, Kuivanen, Ugurlu, Casarotto, Levanov et al., Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro, Front. Pharmacol,
doi:10.3389/fphar.2021.755600Geiger, Kersting, Schlegel, Stelz, Fähr et al., The Acid Ceramidase Is a SARS-CoV-2 Host Factor, Cells,
doi:10.3390/cells11162532Grassme, Riehle, Wilker, Gulbins, Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms, J. Biol. Chem,
doi:10.1074/jbc.M500835200Heilingloh, Aufderhorst, Schipper, Dittmer, Witzke et al., Susceptibility of SARS-CoV-2 to UV irradiation, Am. J. Infect. Control,
doi:10.1016/j.ajic.2020.07.031Herring, Oda, Wagoner, Kirchmeier, O'connor et al., Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs, Antimicrob. Agents Chemother,
doi:10.1128/AAC.01146-20Hoertel, Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality among Patients with COVID-19?, JAMA Netw. Open,
doi:10.1001/jamanetworkopen.2021.36510Hoertel, Rezaei, Sánchez-Rico, Delgado-Álvarez, Kornhuber et al., Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study, Pharmaceuticals,
doi:10.3390/ph16081107Hoertel, Sánchez-Rico, Cougoule, Gulbins, Kornhuber et al., Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: Current evidence and potential mechanisms, Mol. Psychiatry,
doi:10.1038/s41380-021-01254-3Hoffmann, Hofmann-Winkler, Krüger, Kempf, Nehlmeier et al., SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination, Cell Rep,
doi:10.1016/j.celrep.2021.109415Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell,
doi:10.1016/j.cell.2020.02.052Hurwitz, Ferlinz, Sandhoff, The Tricyclic Antidepressant Desipramine Causes Proteolytic Degradation of Lysosomal Sphingomyelinase in Human Fibroblasts, Biol. Chem. Hoppe-Seyler,
doi:10.1515/bchm3.1994.375.7.447Jittamala, Boyd, Schilling, Watson, Ngamprasertchai et al., Antiviral efficacy of fluoxetine in early symptomatic COVID-19: An open-label, randomised, controlled, adaptive platform trial (PLATCOV),
doi:10.1101/2024.01.16.24301337Kornhuber, Tripal, Reichel, Mühle, Rhein et al., Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A novel pharmacological group of drugs with broad clinical applications, Cell Physiol. Biochem,
doi:10.1159/000315101Kutkat, Moatasim, Al-Karmalawy, Abulkhair, Gomaa et al., Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: In vitro and in silico drug repurposing studies, Sci. Rep,
doi:10.1038/s41598-022-17082-6Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients with Symptomatic COVID-19: A Randomized Clinical Trial, JAMA,
doi:10.1001/jama.2020.22760Manganaro, Zonsics, Bauer, Lopez, Donselaar et al., Synthesis and antiviral effect of novel fluoxetine analogues as enterovirus 2C inhibitors, Antivir. Res,
doi:10.1016/j.antiviral.2020.104781Messacar, Sillau, Hopkins, Otten, Wilson-Murphy et al., Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis, Neurology,
doi:10.1212/WNL.0000000000006670Miller, Adhikary, Kolokoltsov, Davey, Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection, J. Virol,
doi:10.1128/JVI.00136-12Oskotsky, Maric, Tang, Oskotsky, Wong et al., Mortality Risk Among Patients with COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants, JAMA Netw Open
Panneer, Kantamaneni, Akkayasamy, Susairaj, Panda et al., The Great Lockdown in the Wake of COVID-19 and Its Implications: Lessons for Low and Middle-Income Countries, Int. J. Environ. Res. Public Health,
doi:10.3390/ijerph19010610Patel, Lim, Cheng, Lawitz, Tillmann et al., Open-label Phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients, Antivir. Ther,
doi:10.3851/IMP1898Péricat, Leon-Icaza, Sanchez Rico, Mühle, Zoicas et al., Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model, Int. J. Mol. Sci,
doi:10.3390/ijms232113623Reis, Dos, Moreira-Silva, Silva, Thabane et al., Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial, Lancet Glob. Health,
doi:10.1016/S2214-109X(21)00448-4Reis, Dos, Silva, Medeiros Silva, Thabane et al., Oral Fluvoxamine with Inhaled Budesonide for Treatment of Early-Onset COVID-19: A Randomized Platform Trial, Ann. Intern. Med,
doi:10.7326/M22-3305Reis, Silva, Silva, Thabane, Milagres et al., Effect of Early Treatment with Ivermectin among Patients with COVID-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2115869Schloer, Brunotte, Goretzko, Mecate-Zambrano, Korthals et al., Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine, Emerg. Microbes Infect,
doi:10.1080/22221751.2020.1829082Seftel, Boulware, Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19, Open Forum. Infect. Dis,
doi:10.1093/ofid/ofab050Thümmler, Gäckler, Bormann, Ciesek, Widera et al., Cellular and Humoral Immunity against Different SARS-CoV-2 Variants Is Detectable but Reduced in Vaccinated Kidney Transplant Patients, Vaccines,
doi:10.3390/vaccines10081348Tseng, Hsu, Ling, Lu, Lin et al., Antidepressant Sertraline Is a Broad-Spectrum Inhibitor of Enteroviruses Targeting Viral Entry through Neutralization of Endolysosomal Acidification, Viruses,
doi:10.3390/v14010109Törnquist, Asghar, Srinivasan, Korhonen, Lindholm, Sphingolipids as Modulators of SARS-CoV-2 Infection, Front. Cell Dev. Biol,
doi:10.3389/fcell.2021.689854Wang, Wei, Hung, Jiang, Li et al., Relationship between antidepressants and severity of SARS-CoV-2 Omicron infection: A retrospective cohort study using real-world data, Lancet Reg. Health West. Pac,
doi:10.1016/j.lanwpc.2023.100716Who, None
Widera, Wilhelm, Toptan, Raffel, Kowarz et al., Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and Cellular Factors Limiting SARS-CoV-2 Replication, Front. Microbiol,
doi:10.3389/fmicb.2021.701198Worldometers, None
Zettl, Meister, Vollmer, Fischer, Steinmann et al., Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes, Vaccines,
doi:10.3390/vaccines8030386Zimniak, Kirschner, Hilpert, Geiger, Danov et al., The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue, Sci. Rep,
doi:10.1038/s41598-021-85049-0Zuo, Quinn, Kye, Cooper, Damoiseaux et al., Fluoxetine Is a Potent Inhibitor of Coxsackievirus Replication, Antimicrob. Agents Chemother,
doi:10.1128/AAC.00983-12DOI record:
{
"DOI": "10.3390/v16040545",
"ISSN": [
"1999-4915"
],
"URL": "http://dx.doi.org/10.3390/v16040545",
"abstract": "<jats:p>The pandemic caused by SARS-CoV-2 is still a major health problem. Newly emerging variants and long-COVID-19 represent a challenge for the global health system. In particular, individuals in developing countries with insufficient health care need easily accessible, affordable and effective treatments of COVID-19. Previous studies have demonstrated the efficacy of functional inhibitors of acid sphingomyelinase against infections with various viruses, including early variants of SARS-CoV-2. This work investigated whether the acid sphingomyelinase inhibitors fluoxetine and sertraline, usually used as antidepressant molecules in clinical practice, can inhibit the replication of the former and recently emerged SARS-CoV-2 variants in vitro. Fluoxetine and sertraline potently inhibited the infection with pseudotyped virus-like particles and SARS-CoV-2 variants D614G, alpha, delta, omicron BA.1 and omicron BA.5. These results highlight fluoxetine and sertraline as priority candidates for large-scale phase 3 clinical trials at different stages of SARS-CoV-2 infections, either alone or in combination with other medications.</jats:p>",
"alternative-id": [
"v16040545"
],
"author": [
{
"ORCID": "http://orcid.org/0000-0003-2034-6255",
"affiliation": [
{
"name": "Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany"
},
{
"name": "Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany"
}
],
"authenticated-orcid": false,
"family": "Thümmler",
"given": "Laura",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany"
}
],
"family": "Beckmann",
"given": "Nadine",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany"
}
],
"family": "Sehl",
"given": "Carolin",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany"
}
],
"family": "Soddemann",
"given": "Matthias",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0003-3169-9515",
"affiliation": [
{
"name": "Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany"
}
],
"authenticated-orcid": false,
"family": "Braß",
"given": "Peer",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-0955-1453",
"affiliation": [
{
"name": "Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany"
}
],
"authenticated-orcid": false,
"family": "Bormann",
"given": "Maren",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany"
}
],
"family": "Brochhagen",
"given": "Leonie",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Institute for Virology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany"
}
],
"family": "Elsner",
"given": "Carina",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Institute Psychiatry and Neuroscience de Paris, INSERM U1266, Paris Cité University, 75014 Paris, France"
},
{
"name": "Psychiatry and Addiction Department Corentin-Celton Hospital (AP-HP), 92130 Paris, France"
}
],
"family": "Hoertel",
"given": "Nicolas",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-6795-5448",
"affiliation": [
{
"name": "Institute of Pharmacology and Structural Biology (IPBS), CNRS, University of Toulouse, UPS, 31000 Toulouse, France"
}
],
"authenticated-orcid": false,
"family": "Cougoule",
"given": "Céline",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Institute of Medical Virology, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany"
},
{
"name": "Institute of Pharmaceutical Biology, Goethe-University, 60323 Frankfurt am Main, Germany"
},
{
"name": "Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch Translational Medicine and Pharmacology, 60311 Frankfurt am Main, Germany"
}
],
"family": "Ciesek",
"given": "Sandra",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Institute of Medical Virology, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany"
}
],
"family": "Widera",
"given": "Marek",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Institute for Virology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany"
}
],
"family": "Dittmer",
"given": "Ulf",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-6708-4390",
"affiliation": [
{
"name": "Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany"
}
],
"authenticated-orcid": false,
"family": "Lindemann",
"given": "Monika",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Institute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany"
}
],
"family": "Horn",
"given": "Peter A.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany"
}
],
"family": "Witzke",
"given": "Oliver",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-6430-1230",
"affiliation": [
{
"name": "Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany"
}
],
"authenticated-orcid": false,
"family": "Kadow",
"given": "Stephanie",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-6608-8496",
"affiliation": [
{
"name": "Department of Thoracic and Cardiovascular Surgery, West German Heart Center, University Hospital Essen, 45147 Essen, Germany"
}
],
"authenticated-orcid": false,
"family": "Kamler",
"given": "Markus",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany"
}
],
"family": "Gulbins",
"given": "Erich",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-6317-7298",
"affiliation": [
{
"name": "Institute of Molecular Biology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany"
}
],
"authenticated-orcid": false,
"family": "Becker",
"given": "Katrin Anne",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0001-9502-9903",
"affiliation": [
{
"name": "Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany"
},
{
"name": "Institute for Virology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany"
}
],
"authenticated-orcid": false,
"family": "Krawczyk",
"given": "Adalbert",
"sequence": "additional"
}
],
"container-title": "Viruses",
"container-title-short": "Viruses",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2024,
3,
31
]
],
"date-time": "2024-03-31T17:44:52Z",
"timestamp": 1711907092000
},
"deposited": {
"date-parts": [
[
2024,
4,
2
]
],
"date-time": "2024-04-02T04:37:42Z",
"timestamp": 1712032662000
},
"indexed": {
"date-parts": [
[
2024,
4,
3
]
],
"date-time": "2024-04-03T01:25:35Z",
"timestamp": 1712107535605
},
"is-referenced-by-count": 0,
"issue": "4",
"issued": {
"date-parts": [
[
2024,
3,
30
]
]
},
"journal-issue": {
"issue": "4",
"published-online": {
"date-parts": [
[
2024,
4
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://creativecommons.org/licenses/by/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2024,
3,
30
]
],
"date-time": "2024-03-30T00:00:00Z",
"timestamp": 1711756800000
}
}
],
"link": [
{
"URL": "https://www.mdpi.com/1999-4915/16/4/545/pdf",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "1968",
"original-title": [],
"page": "545",
"prefix": "10.3390",
"published": {
"date-parts": [
[
2024,
3,
30
]
]
},
"published-online": {
"date-parts": [
[
2024,
3,
30
]
]
},
"publisher": "MDPI AG",
"reference": [
{
"key": "ref_1",
"unstructured": "(2024, January 08). Worldometers. Available online: https://www.worldometers.info/coronavirus/."
},
{
"DOI": "10.3390/ijerph19010610",
"doi-asserted-by": "crossref",
"key": "ref_2",
"unstructured": "Panneer, S., Kantamaneni, K., Akkayasamy, V.S., Susairaj, A.X., Panda, P.K., Acharya, S.S., Rice, L., Liyanage, C., and Pushparaj, R.R.B. (2022). The Great Lockdown in the Wake of COVID-19 and Its Implications: Lessons for Low and Middle-Income Countries. Int. J. Environ. Res. Public Health, 19."
},
{
"DOI": "10.1038/s41591-023-02282-y",
"article-title": "Determinants of COVID-19 vaccine fatigue",
"author": "Stamm",
"doi-asserted-by": "crossref",
"first-page": "1164",
"journal-title": "Nat. Med.",
"key": "ref_3",
"volume": "29",
"year": "2023"
},
{
"DOI": "10.3389/fimmu.2023.1150667",
"article-title": "Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5",
"author": "Bormann",
"doi-asserted-by": "crossref",
"first-page": "1150667",
"journal-title": "Front. Immunol.",
"key": "ref_4",
"volume": "14",
"year": "2023"
},
{
"DOI": "10.1056/NEJMoa2109072",
"article-title": "Covid-19 Breakthrough Infections in Vaccinated Health Care Workers",
"author": "Bergwerk",
"doi-asserted-by": "crossref",
"first-page": "1474",
"journal-title": "N. Engl. J. Med.",
"key": "ref_5",
"volume": "385",
"year": "2021"
},
{
"DOI": "10.1007/s44197-023-00090-8",
"article-title": "COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates",
"author": "Dash",
"doi-asserted-by": "crossref",
"first-page": "67",
"journal-title": "J. Epidemiol. Glob. Health",
"key": "ref_6",
"volume": "13",
"year": "2023"
},
{
"DOI": "10.1128/jvi.01245-22",
"article-title": "Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein",
"author": "Chen",
"doi-asserted-by": "crossref",
"first-page": "e01245-22",
"journal-title": "J. Virol.",
"key": "ref_7",
"volume": "96",
"year": "2022"
},
{
"DOI": "10.1016/j.antiviral.2020.104781",
"article-title": "Synthesis and antiviral effect of novel fluoxetine analogues as enterovirus 2C inhibitors",
"author": "Manganaro",
"doi-asserted-by": "crossref",
"first-page": "104781",
"journal-title": "Antivir. Res.",
"key": "ref_8",
"volume": "178",
"year": "2020"
},
{
"DOI": "10.1212/WNL.0000000000006670",
"article-title": "Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis",
"author": "Messacar",
"doi-asserted-by": "crossref",
"first-page": "E2118",
"journal-title": "Neurology",
"key": "ref_9",
"volume": "92",
"year": "2019"
},
{
"DOI": "10.3390/v14010109",
"doi-asserted-by": "crossref",
"key": "ref_10",
"unstructured": "Tseng, K.C., Hsu, B.Y., Ling, P., Lu, W.W., Lin, C.W., and Kung, S.H. (2022). Antidepressant Sertraline Is a Broad-Spectrum Inhibitor of Enteroviruses Targeting Viral Entry through Neutralization of Endolysosomal Acidification. Viruses, 14."
},
{
"DOI": "10.1128/AAC.00983-12",
"article-title": "Fluoxetine Is a Potent Inhibitor of Coxsackievirus Replication",
"author": "Zuo",
"doi-asserted-by": "crossref",
"first-page": "4838",
"journal-title": "Antimicrob. Agents Chemother.",
"key": "ref_11",
"volume": "56",
"year": "2012"
},
{
"DOI": "10.3851/IMP1898",
"article-title": "Open-label Phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients",
"author": "Patel",
"doi-asserted-by": "crossref",
"first-page": "1341",
"journal-title": "Antivir. Ther.",
"key": "ref_12",
"volume": "16",
"year": "2011"
},
{
"DOI": "10.1128/AAC.01146-20",
"article-title": "Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs",
"author": "Herring",
"doi-asserted-by": "crossref",
"first-page": "e01146-20",
"journal-title": "Antimicrob. Agents Chemother.",
"key": "ref_13",
"volume": "65",
"year": "2021"
},
{
"DOI": "10.1007/BF00500076",
"article-title": "Lipid and lysosomal enzymes in human fibroblasts cultured with perhexiline maleate",
"author": "Albouz",
"doi-asserted-by": "crossref",
"first-page": "173",
"journal-title": "Naunyn-Schmiedebergs Arch. Pharmacol.",
"key": "ref_14",
"volume": "317",
"year": "1981"
},
{
"DOI": "10.1515/bchm3.1994.375.7.447",
"article-title": "The Tricyclic Antidepressant Desipramine Causes Proteolytic Degradation of Lysosomal Sphingomyelinase in Human Fibroblasts",
"author": "Hurwitz",
"doi-asserted-by": "crossref",
"first-page": "447",
"journal-title": "Biol. Chem. Hoppe-Seyler",
"key": "ref_15",
"volume": "375",
"year": "1994"
},
{
"DOI": "10.1159/000315101",
"article-title": "Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A novel pharmacological group of drugs with broad clinical applications",
"author": "Kornhuber",
"doi-asserted-by": "crossref",
"first-page": "9",
"journal-title": "Cell Physiol. Biochem.",
"key": "ref_16",
"volume": "26",
"year": "2010"
},
{
"DOI": "10.1038/s41598-021-85049-0",
"article-title": "The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue",
"author": "Zimniak",
"doi-asserted-by": "crossref",
"first-page": "5890",
"journal-title": "Sci. Rep.",
"key": "ref_17",
"volume": "11",
"year": "2021"
},
{
"DOI": "10.1038/s41598-022-17082-6",
"article-title": "Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: In vitro and in silico drug repurposing studies",
"author": "Kutkat",
"doi-asserted-by": "crossref",
"first-page": "12920",
"journal-title": "Sci. Rep.",
"key": "ref_18",
"volume": "12",
"year": "2022"
},
{
"DOI": "10.3390/ijms232113623",
"doi-asserted-by": "crossref",
"key": "ref_19",
"unstructured": "Péricat, D., Leon-Icaza, S.A., Sanchez Rico, M., Mühle, C., Zoicas, I., Schumacher, F., Planès, R., Mazars, R., Gros, G., and Carpinteiro, A. (2022). Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model. Int. J. Mol. Sci., 23."
},
{
"DOI": "10.1001/jama.2020.22760",
"article-title": "Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients with Symptomatic COVID-19: A Randomized Clinical Trial",
"author": "Lenze",
"doi-asserted-by": "crossref",
"first-page": "2292",
"journal-title": "JAMA",
"key": "ref_20",
"volume": "324",
"year": "2020"
},
{
"DOI": "10.1111/bcp.15126",
"article-title": "Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls",
"author": "Calusic",
"doi-asserted-by": "crossref",
"first-page": "2065",
"journal-title": "Br. J. Clin. Pharmacol.",
"key": "ref_21",
"volume": "88",
"year": "2022"
},
{
"DOI": "10.1093/ofid/ofab050",
"article-title": "Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19",
"author": "Seftel",
"doi-asserted-by": "crossref",
"first-page": "ofab050",
"journal-title": "Open Forum. Infect. Dis.",
"key": "ref_22",
"volume": "8",
"year": "2021"
},
{
"DOI": "10.1056/NEJMoa2115869",
"article-title": "Effect of Early Treatment with Ivermectin among Patients with COVID-19",
"author": "Reis",
"doi-asserted-by": "crossref",
"first-page": "1721",
"journal-title": "N. Engl. J. Med.",
"key": "ref_23",
"volume": "386",
"year": "2022"
},
{
"DOI": "10.1016/j.xcrm.2020.100142",
"article-title": "Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells",
"author": "Carpinteiro",
"doi-asserted-by": "crossref",
"first-page": "100142",
"journal-title": "Cell Rep. Med.",
"key": "ref_24",
"volume": "1",
"year": "2020"
},
{
"DOI": "10.1016/j.jbc.2021.100701",
"doi-asserted-by": "crossref",
"key": "ref_25",
"unstructured": "Carpinteiro, A., Gripp, B., Hoffmann, M., Pöhlmann, S., Hoertel, N., Edwards, M.J., Kamler, M., Kornhuber, J., Becker, K.A., and Gulbins, E. (2021). Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. J. Biol. Chem., 296."
},
{
"DOI": "10.1001/jamanetworkopen.2021.36510",
"article-title": "Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality among Patients with COVID-19?",
"author": "Hoertel",
"doi-asserted-by": "crossref",
"first-page": "e2136510",
"journal-title": "JAMA Netw. Open",
"key": "ref_26",
"volume": "4",
"year": "2021"
},
{
"DOI": "10.1038/s41380-021-01254-3",
"article-title": "Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: Current evidence and potential mechanisms",
"author": "Hoertel",
"doi-asserted-by": "crossref",
"first-page": "7098",
"journal-title": "Mol. Psychiatry",
"key": "ref_27",
"volume": "26",
"year": "2021"
},
{
"DOI": "10.3389/fmicb.2021.701198",
"doi-asserted-by": "crossref",
"key": "ref_28",
"unstructured": "Widera, M., Wilhelm, A., Toptan, T., Raffel, J.M., Kowarz, E., Roesmann, F., Grozinger, F., Siemund, A.L., Luciano, V., and Kulp, M. (2021). Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and Cellular Factors Limiting SARS-CoV-2 Replication. Front. Microbiol., 12."
},
{
"DOI": "10.3390/vaccines10081348",
"doi-asserted-by": "crossref",
"key": "ref_29",
"unstructured": "Thümmler, L., Gäckler, A., Bormann, M., Ciesek, S., Widera, M., Rohn, H., Fisenkci, N., Otte, M., Alt, M., and Dittmer, U. (2022). Cellular and Humoral Immunity against Different SARS-CoV-2 Variants Is Detectable but Reduced in Vaccinated Kidney Transplant Patients. Vaccines, 10."
},
{
"key": "ref_30",
"unstructured": "(2024, January 09). WHO. Available online: https://www.who.int/activities/tracking-SARS-CoV-2-variants."
},
{
"DOI": "10.1016/j.ajic.2020.07.031",
"article-title": "Susceptibility of SARS-CoV-2 to UV irradiation",
"author": "Heilingloh",
"doi-asserted-by": "crossref",
"first-page": "1273",
"journal-title": "Am. J. Infect. Control",
"key": "ref_31",
"volume": "48",
"year": "2020"
},
{
"DOI": "10.1016/j.cell.2020.02.052",
"article-title": "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor",
"author": "Hoffmann",
"doi-asserted-by": "crossref",
"first-page": "271",
"journal-title": "Cell",
"key": "ref_32",
"volume": "181",
"year": "2020"
},
{
"DOI": "10.1371/journal.pone.0025858",
"doi-asserted-by": "crossref",
"key": "ref_33",
"unstructured": "Berger Rentsch, M., and Zimmer, G. (2011). A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PLoS ONE, 6."
},
{
"DOI": "10.1016/j.xpro.2021.100356",
"article-title": "Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells",
"author": "Becker",
"doi-asserted-by": "crossref",
"first-page": "100356",
"journal-title": "STAR Protoc.",
"key": "ref_34",
"volume": "2",
"year": "2021"
},
{
"DOI": "10.3390/vaccines8030386",
"doi-asserted-by": "crossref",
"key": "ref_35",
"unstructured": "Zettl, F., Meister, T.L., Vollmer, T., Fischer, B., Steinmann, J., Krawczyk, A., V’kovski, P., Todt, D., Steinmann, E., and Pfaender, S. (2020). Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. Vaccines, 8."
},
{
"DOI": "10.1016/j.celrep.2021.109415",
"article-title": "SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination",
"author": "Hoffmann",
"doi-asserted-by": "crossref",
"first-page": "109415",
"journal-title": "Cell Rep.",
"key": "ref_36",
"volume": "36",
"year": "2021"
},
{
"DOI": "10.3389/fphar.2021.755600",
"article-title": "Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro",
"author": "Fred",
"doi-asserted-by": "crossref",
"first-page": "755600",
"journal-title": "Front. Pharmacol.",
"key": "ref_37",
"volume": "12",
"year": "2021"
},
{
"DOI": "10.3390/cells11162532",
"doi-asserted-by": "crossref",
"key": "ref_38",
"unstructured": "Geiger, N., Kersting, L., Schlegel, J., Stelz, L., Fähr, S., Diesendorf, V., Roll, V., Sostmann, M., König, E.-M., and Reinhard, S. (2022). The Acid Ceramidase Is a SARS-CoV-2 Host Factor. Cells, 11."
},
{
"DOI": "10.1080/22221751.2020.1829082",
"article-title": "Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine",
"author": "Schloer",
"doi-asserted-by": "crossref",
"first-page": "2245",
"journal-title": "Emerg. Microbes Infect.",
"key": "ref_39",
"volume": "9",
"year": "2020"
},
{
"DOI": "10.1038/s41380-021-01309-5",
"article-title": "The acid sphingomyelinase/ceramide system in COVID-19",
"author": "Kornhuber",
"doi-asserted-by": "crossref",
"first-page": "307",
"journal-title": "Mol. Psychiatry",
"key": "ref_40",
"volume": "27",
"year": "2022"
},
{
"DOI": "10.3389/fcell.2021.689854",
"doi-asserted-by": "crossref",
"key": "ref_41",
"unstructured": "Törnquist, K., Asghar, M.Y., Srinivasan, V., Korhonen, L., and Lindholm, D. (2021). Sphingolipids as Modulators of SARS-CoV-2 Infection. Front. Cell Dev. Biol., 9."
},
{
"DOI": "10.3390/ijms22115676",
"doi-asserted-by": "crossref",
"key": "ref_42",
"unstructured": "Beckmann, N., and Becker, K.A. (2021). Ceramide and Related Molecules in Viral Infections. Int. J. Mol. Sci., 22."
},
{
"DOI": "10.1038/s41380-021-01432-3",
"article-title": "Mechanisms of action of fluvoxamine for COVID-19: A historical review",
"author": "Hashimoto",
"doi-asserted-by": "crossref",
"first-page": "1898",
"journal-title": "Mol. Psychiatry",
"key": "ref_43",
"volume": "27",
"year": "2022"
},
{
"DOI": "10.1074/jbc.M500835200",
"article-title": "Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms",
"author": "Grassme",
"doi-asserted-by": "crossref",
"first-page": "26256",
"journal-title": "J. Biol. Chem.",
"key": "ref_44",
"volume": "280",
"year": "2005"
},
{
"DOI": "10.1128/JVI.00136-12",
"article-title": "Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection",
"author": "Miller",
"doi-asserted-by": "crossref",
"first-page": "7473",
"journal-title": "J. Virol.",
"key": "ref_45",
"volume": "86",
"year": "2012"
},
{
"DOI": "10.3390/ph16081107",
"doi-asserted-by": "crossref",
"key": "ref_46",
"unstructured": "Hoertel, N., Rezaei, K., Sánchez-Rico, M., Delgado-Álvarez, A., Kornhuber, J., Gulbins, E., Olfson, M., Ouazana-Vedrines, C., Carpinteiro, A., and Cougoule, C. (2023). Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study. Pharmaceuticals, 16."
},
{
"DOI": "10.7326/M22-3305",
"article-title": "Oral Fluvoxamine with Inhaled Budesonide for Treatment of Early-Onset COVID-19: A Randomized Platform Trial",
"author": "Reis",
"doi-asserted-by": "crossref",
"first-page": "667",
"journal-title": "Ann. Intern. Med.",
"key": "ref_47",
"volume": "176",
"year": "2023"
},
{
"DOI": "10.1016/j.lanwpc.2023.100716",
"article-title": "Relationship between antidepressants and severity of SARS-CoV-2 Omicron infection: A retrospective cohort study using real-world data",
"author": "Wang",
"doi-asserted-by": "crossref",
"first-page": "100716",
"journal-title": "Lancet Reg. Health West. Pac.",
"key": "ref_48",
"volume": "34",
"year": "2023"
},
{
"DOI": "10.1101/2024.01.16.24301337",
"doi-asserted-by": "crossref",
"key": "ref_49",
"unstructured": "Jittamala, P., Boyd, S., Schilling, W.H., Watson, J.A., Ngamprasertchai, T., Siripoon, T., Luvira, V., Batty, E.M., Wongnak, P., and Esper, L.M. (2024). Antiviral efficacy of fluoxetine in early symptomatic COVID-19: An open-label, randomised, controlled, adaptive platform trial (PLATCOV). medRxiv."
},
{
"DOI": "10.1016/S2214-109X(21)00448-4",
"article-title": "Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial",
"author": "Reis",
"doi-asserted-by": "crossref",
"first-page": "e42",
"journal-title": "Lancet Glob. Health",
"key": "ref_50",
"volume": "10",
"year": "2022"
},
{
"DOI": "10.1001/jamanetworkopen.2021.33090",
"article-title": "Mortality Risk Among Patients with COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants",
"author": "Oskotsky",
"doi-asserted-by": "crossref",
"first-page": "e2133090",
"journal-title": "JAMA Netw Open",
"key": "ref_51",
"volume": "4",
"year": "2021"
}
],
"reference-count": 51,
"references-count": 51,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.mdpi.com/1999-4915/16/4/545"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Virology",
"Infectious Diseases"
],
"subtitle": [],
"title": "Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants",
"type": "journal-article",
"volume": "16"
}
